Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: SPOR Innovative Clinical Trials (iCT)

University of Calgary

$99,724.00

Establishing the foundation for a patient-centered pragmatic registry-randomized trial of treatment tapering in rheumatoid arthritis

EF 2016-17

Résumé
Rheumatoid arthritis is a chronic autoimmune disease that affects up to 1% of the adult population and causes fatigue, joint pain, swelling and a reduced quality of life. Fortunately, the treatment for rheumatoid arthritis has advanced, and most patients can now have their disease effectively controlled with medications. After a patient's disease has been successfully treated and controlled, the usual practice is to continue with these medications for life. Emerging evidence suggests some patients may be able to successfully reduce medication once their disease is under control, but this evidence has important limitations, and more clinical trials are needed. To understand when and how to best reduce treatment however, we also must understand patients' preferences. Patients may have strong desires or fears about reducing their treatment, which we must understand and incorporate into decision-making. In this catalyst grant, we will conduct studies to understand the preferences of patients with rheumatoid arthritis, as well as physicians of patients with rheumatoid arthritis, around a decision to reduce treatment. We will use this information to develop a tapering approach that incorporates both patients' and physicians' preferences alongside best current evidence. We will then assess the feasibility of a potential randomized trial to compare this tapering approach to the current standard care. We will conduct this feasibility study by surveying patients already enrolled in a large ongoing cross-Canadian study following patients with early rheumatoid arthritis from first diagnosis. This research will help us design a clinical trial that compares treatment tapering to usual care, and will forge strong relationships between patients, physicians, researchers, and guideline and health policy leaders. This will create an effective and transformative partnership with the aim of generating clinical trial research that is more aligned with patients' preferences.
Programme
Catalyst Grant: SPOR Innovative Clinical Trials (iCT)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
358963
Name
Hazlewood Glen S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Catalyst Grant SPOR Innovative Clinical Trials
Projecttitle
Establishing the foundation for a patient-centered pragmatic registry-randomized trial of treatment tapering in rheumatoid arthritis
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$99,724
Cihrequipment2
$0
Programname2
Catalyst Grant: SPOR Innovative Clinical Trials (iCT)
Keyworddelim
Discrete-Choice Experiment; Patient Preferences; Physician Preferences; Pragmatic Randomized Trials; Qualitative Research; Rheumatoid Arthritis; Treatment Tapering
Abstract
Rheumatoid arthritis is a chronic autoimmune disease that affects up to 1% of the adult population and causes fatigue, joint pain, swelling and a reduced quality of life. Fortunately, the treatment for rheumatoid arthritis has advanced, and most patients can now have their disease effectively controlled with medications. After a patient's disease has been successfully treated and controlled, the usual practice is to continue with these medications for life. Emerging evidence suggests some patients may be able to successfully reduce medication once their disease is under control, but this evidence has important limitations, and more clinical trials are needed. To understand when and how to best reduce treatment however, we also must understand patients' preferences. Patients may have strong desires or fears about reducing their treatment, which we must understand and incorporate into decision-making. In this catalyst grant, we will conduct studies to understand the preferences of patients with rheumatoid arthritis, as well as physicians of patients with rheumatoid arthritis, around a decision to reduce treatment. We will use this information to develop a tapering approach that incorporates both patients' and physicians' preferences alongside best current evidence. We will then assess the feasibility of a potential randomized trial to compare this tapering approach to the current standard care. We will conduct this feasibility study by surveying patients already enrolled in a large ongoing cross-Canadian study following patients with early rheumatoid arthritis from first diagnosis. This research will help us design a clinical trial that compares treatment tapering to usual care, and will forge strong relationships between patients, physicians, researchers, and guideline and health policy leaders. This will create an effective and transformative partnership with the aim of generating clinical trial research that is more aligned with patients' preferences.
Competitiondate
201609
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hazlewood, Glen S; Richards, Dawn; Bartlett, Susan J; Bykerk, Vivian P; Marshall, Deborah A; Pope, Janet E; Wells, George A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,724~ $0~